China Shineway Pharmaceutical Group Limited (C1S) - Net Assets
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) has net assets worth €7.81 Billion EUR (≈ $9.13 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.39 Billion ≈ $12.14 Billion USD) and total liabilities (€2.58 Billion ≈ $3.01 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check China Shineway Pharmaceutical Group Limi liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.81 Billion |
| % of Total Assets | 75.18% |
| Annual Growth Rate | 4.86% |
| 5-Year Change | 28.87% |
| 10-Year Change | 40.99% |
| Growth Volatility | 3.97 |
China Shineway Pharmaceutical Group Limited - Net Assets Trend (2013–2024)
This chart illustrates how China Shineway Pharmaceutical Group Limited's net assets have evolved over time, based on quarterly financial data. Also explore C1S total assets for the complete picture of this company's asset base.
Annual Net Assets for China Shineway Pharmaceutical Group Limited (2013–2024)
The table below shows the annual net assets of China Shineway Pharmaceutical Group Limited from 2013 to 2024. For live valuation and market cap data, see market cap of China Shineway Pharmaceutical Group Limi.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.47 Billion ≈ $8.73 Billion |
+6.14% |
| 2023-12-31 | €7.03 Billion ≈ $8.22 Billion |
+10.22% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
+8.15% |
| 2021-12-31 | €5.90 Billion ≈ $6.90 Billion |
+1.85% |
| 2020-12-31 | €5.79 Billion ≈ $6.77 Billion |
+0.30% |
| 2019-12-31 | €5.78 Billion ≈ $6.75 Billion |
+0.19% |
| 2018-12-31 | €5.77 Billion ≈ $6.74 Billion |
-0.95% |
| 2017-12-31 | €5.82 Billion ≈ $6.81 Billion |
+3.45% |
| 2016-12-31 | €5.63 Billion ≈ $6.58 Billion |
+6.24% |
| 2015-12-31 | €5.30 Billion ≈ $6.19 Billion |
+8.24% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
+10.46% |
| 2013-12-31 | €4.43 Billion ≈ $5.18 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to China Shineway Pharmaceutical Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 93.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €6.73 Billion | 90.08% |
| Other Components | €740.47 Million | 9.92% |
| Total Equity | €7.47 Billion | 100.00% |
China Shineway Pharmaceutical Group Limited Competitors by Market Cap
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
$785.64 Million |
|
Whitestone REIT
NYSE:WSR
|
$785.80 Million |
|
Sumber Tani Agung Resources Tbk PT
JK:STAA
|
$785.84 Million |
|
China Building Material
SHG:603060
|
$785.87 Million |
|
TOA Paint (Thailand) Public Company Limited
BK:TOA
|
$785.51 Million |
|
Mahindra Lifespace Developers Limited
NSE:MAHLIFE
|
$785.50 Million |
|
First Financial Corporation Indiana
NASDAQ:THFF
|
$785.20 Million |
|
Paul Hartmann AG
F:PHH2
|
$784.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Shineway Pharmaceutical Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,034,768,000 to 7,466,904,000, a change of 432,136,000 (6.1%).
- Net income of 840,052,000 contributed positively to equity growth.
- Dividend payments of 407,916,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €840.05 Million | +11.25% |
| Dividends Paid | €407.92 Million | -5.46% |
| Total Change | €- | 6.14% |
Book Value vs Market Value Analysis
This analysis compares China Shineway Pharmaceutical Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €7.04 | €1.06 | x |
| 2018-12-31 | €6.97 | €1.06 | x |
| 2019-12-31 | €6.99 | €1.06 | x |
| 2020-12-31 | €7.01 | €1.06 | x |
| 2021-12-31 | €7.14 | €1.06 | x |
| 2022-12-31 | €7.72 | €1.06 | x |
| 2023-12-31 | €8.51 | €1.06 | x |
| 2024-12-31 | €9.88 | €1.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Shineway Pharmaceutical Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.25%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.24%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.34x
- Recent ROE (11.25%) is above the historical average (10.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 15.44% | 31.26% | 0.38x | 1.30x | €240.74 Million |
| 2014 | 14.41% | 31.62% | 0.38x | 1.21x | €215.53 Million |
| 2015 | 12.42% | 32.02% | 0.33x | 1.16x | €128.31 Million |
| 2016 | 10.47% | 29.56% | 0.31x | 1.15x | €26.53 Million |
| 2017 | 7.76% | 23.52% | 0.29x | 1.15x | €-130.54 Million |
| 2018 | 8.77% | 19.68% | 0.38x | 1.17x | €-70.70 Million |
| 2019 | 8.71% | 18.59% | 0.38x | 1.23x | €-74.54 Million |
| 2020 | 5.09% | 11.11% | 0.37x | 1.24x | €-284.39 Million |
| 2021 | 9.43% | 17.27% | 0.45x | 1.22x | €-33.47 Million |
| 2022 | 11.32% | 18.30% | 0.48x | 1.29x | €84.52 Million |
| 2023 | 13.78% | 21.47% | 0.47x | 1.36x | €266.03 Million |
| 2024 | 11.25% | 22.24% | 0.38x | 1.34x | €93.36 Million |
Industry Comparison
This section compares China Shineway Pharmaceutical Group Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $778,651,241
- Average return on equity (ROE) among peers: -82.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Shineway Pharmaceutical Group Limited (C1S) | €7.81 Billion | 15.44% | 0.33x | $785.62 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.07 Billion | 1.94% | 0.48x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $9.58 Million | -63.03% | 0.52x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $3.54 Million | -57.78% | 0.18x | $1.75 Million |
| Apontis Pharma AG (APPH) | $40.71 Million | -1.83% | 0.33x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more